Ultomiris And Successor Key To AstraZeneca’s Rare Disease Ambitions
Room For Growth In Rare Diseases
Executive Summary
Having completed its $39bn takeover of Alexion, AstraZeneca must now demonstrate its ability to maximize revenues and performance from the US rare disease specialist.